Home » Stocks » ATOS

Atossa Therapeutics, Inc. (ATOS)

Stock Price: $2.23 USD 0.09 (4.21%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $2.29 +0.06 (2.69%) Mar 5, 7:58 PM
Market Cap 159.61M
Revenue (ttm) n/a
Net Income (ttm) -12.96M
Shares Out 10.16M
EPS (ttm) -1.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $2.23
Previous Close $2.14
Change ($) 0.09
Change (%) 4.21%
Day's Open 2.19
Day's Range 1.78 - 2.34
Day's Volume 12,578,250
52-Week Range 0.76 - 5.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 6 days ago

It's fine to own ATOS stock based on the Covid-19 angle, but a broader view of the company reveals a commitment to under-treated conditions. The post Atossa Therapeutics Has a Covid-19 Connect...

Benzinga - 1 week ago

Atossa Therapeutics Inc (NASDAQ: ATOS) announces final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients rece...

GlobeNewsWire - 3 weeks ago

SEATTLE, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...

The Motley Fool - 1 month ago

Investors are excited about the potential of the biotech's experimental breast cancer treatment.

InvestorPlace - 1 month ago

Atossa Therapeutics (ATOS) stock is on the rise with heavy trading Thursday after announcing some positive breast cancer news. The post ATOS Stock: 8 Things for Investors to Know About Atossa ...

GlobeNewsWire - 1 month ago

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...

GlobeNewsWire - 1 month ago

SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...

GlobeNewsWire - 1 month ago

SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...

PRNewsWire - 1 month ago

SEATTLE, Jan. 29, 2021 /PRNewswire/ -- A paper was published today by Dr. Steven Quay, M.D., PhD., CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS), entitled, "A Bayesian analysis concludes bey...

GlobeNewsWire - 1 month ago

SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...

PRNewsWire - 1 month ago

HOUSTON, Jan. 8, 2021 /PRNewswire/ -- Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS ), recently shared his latest research a...

GlobeNewsWire - 2 months ago

SEATTLE, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop inno...

GlobeNewsWire - 2 months ago

SEATTLE, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop inno...

GlobeNewsWire - 2 months ago

SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...

GlobeNewsWire - 3 months ago

SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...

GlobeNewsWire - 3 months ago

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...

PRNewsWire - 4 months ago

SEATTLE, Oct. 28, 2020 /PRNewswire/ -- A paper published on Zenodo (DOI 10.5281/zenodo.4119263) by Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics...

GlobeNewsWire - 4 months ago

SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...

GlobeNewsWire - 5 months ago

In honor of October Breast Cancer Awareness Month, Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse will deliver a presentation titled “Atossa Therapeutics: Tackling our Greatest Heal...

PRNewsWire - 5 months ago

SEATTLE, Oct. 2, 2020 /PRNewswire/ -- Renowned physician-scientist Dr. Steven Quay, MD, PhD, and CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS) has provided 50 copies of his best-selling book...

GlobeNewsWire - 5 months ago

SEATTLE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas...

GlobeNewsWire - 5 months ago

Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study Arm Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study Arm

GlobeNewsWire - 6 months ago

SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas...

Investopedia - 6 months ago

Volatility can be your best friend if you trade based on chart patterns. These penny stocks could be profitable in tumultuous times.

Other stocks mentioned: GVP, TATT, WTT, YRD
GlobeNewsWire - 6 months ago

SEATTLE, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...

GlobeNewsWire - 6 months ago

SEATTLE, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...

GlobeNewsWire - 6 months ago

SEATTLE, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...

GlobeNewsWire - 7 months ago

Enrollment Expected to Begin Within 30 days Enrollment Expected to Begin Within 30 days

GlobeNewsWire - 7 months ago

Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer...

GlobeNewsWire - 7 months ago

Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two COVID-19 treatment programs Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two ...

GlobeNewsWire - 7 months ago

SEATTLE, July 16, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...

GlobeNewsWire - 7 months ago

Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients

GlobeNewsWire - 7 months ago

SEATTLE, July 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...

GlobeNewsWire - 8 months ago

SEATTLE, June 11, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...

Seeking Alpha - 9 months ago

Atossa Therapeutics: Feeling Bullish About COVID-19 Program

GlobeNewsWire - 9 months ago

AT-301 Intended to Prevent COVID-19 and Treat Early Cases Via Nasal Delivery AT-301 Intended to Prevent COVID-19 and Treat Early Cases Via Nasal Delivery

Benzinga - 9 months ago

Atossa Therapeutics (NASDAQ: ATOS) shares are trading higher on Wednesday. The company announced "successful" in vitro testing results of AT-H201, which is Atossa's proprietary COVID-19 drug c...

GlobeNewsWire - 9 months ago

Results Support Development of AT-H201 for COVID-19 Patients Results Support Development of AT-H201 for COVID-19 Patients

GlobeNewsWire - 9 months ago

SEATTLE, May 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas o...

GlobeNewsWire - 10 months ago

SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in area...

24/7 Wall Street - 10 months ago

Atossa Therapeutics Inc. (NASDAQ: ATOS) is the newest company to join the fight against COVID-19.

GlobeNewsWire - 10 months ago

Combination of two drugs previously approved by the FDA for other diseases to be developed to reduce patient time on a ventilator Combination of two drugs previously approved by the FDA for ot...

GlobeNewsWire - 11 months ago

Company’s Clinical Development Has Not Been Impacted by COVID-19 Company’s Clinical Development Has Not Been Impacted by COVID-19

Seeking Alpha - 1 year ago

Speculative Spotlight: Atossa Therapeutics Offers An Enticing Risk-Reward

GlobeNewsWire - 1 year ago

SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders:

GlobeNewsWire - 1 year ago

SEATTLE, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast ca...

GlobeNewsWire - 1 year ago

SEATTLE, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast ca...

GlobeNewsWire - 1 year ago

Susan Love, M.D., inventor of the technology, will advise Atossa on the study Susan Love, M.D., inventor of the technology, will advise Atossa on the study

GlobeNewsWire - 1 year ago

All Objectives Successfully Met – Phase 2 Study to Start Q4 2019 All Objectives Successfully Met – Phase 2 Study to Start Q4 2019

GlobeNewsWire - 1 year ago

SEATTLE, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast c...

About ATOS

Atossa Therapeutics develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was f... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 2012
CEO
Steven Quay
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
ATOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ATOS stock is "Buy." The 12-month stock price forecast is 6.25, which is an increase of 180.27% from the latest price.

Price Target
$6.25
(180.27% upside)
Analyst Consensus: Buy